Compare QSI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QSI | PCRX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 1.0B |
| IPO Year | N/A | 2010 |
| Metric | QSI | PCRX |
|---|---|---|
| Price | $0.85 | $23.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.00 | ★ $37.60 |
| AVG Volume (30 Days) | ★ 2.7M | 801.0K |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $196.35 | $9.77 |
| Revenue Next Year | $229.03 | $9.71 |
| P/E Ratio | ★ N/A | $138.44 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $0.83 | $18.80 |
| 52 Week High | $3.10 | $27.99 |
| Indicator | QSI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.20 | 55.01 |
| Support Level | N/A | $22.57 |
| Resistance Level | $1.11 | $23.91 |
| Average True Range (ATR) | 0.06 | 0.98 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 19.03 | 67.69 |
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.